Avisa Diagnostics Inc(FOGCF)
USD --+0.00%
Reward41Moderate
Risk68Medium-High
📊75%Data
Thin -258% profit margin · Revenue down 50% YoY
FOGCF
+0.0 · +0.00%
USD · PINK
Avisa Diagnostics Inc | Healthcare
Earnings Deterioration
Market Cap:50
ℹ️
Reward Rating
41
Moderate
Bottom 10% (model universe)
75% data coverage
ℹ️
Risk Rating
68
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on FOGCF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Avisa Diagnostics Inc?

operates a clinical-stage medical device company.

FOGCF · Verdict

Moderate reward · elevated risk

FOGCF's standout is volatility; cash flow and balance sheet weigh on the picture.

Based on 88% data coverage

FOGCF · Verdict

What’s working & what to watch

Strengths 1

  • Volatility95/100

    Top decile vs peers

Watchouts 4

  • Cash flow6/100

    -163% free-cash-flow margin

  • Balance sheet14/100

    Current ratio 0.23

  • Profitability19/100

    -258% net margin · -289% ROE

  • Growth41/100

    Earnings +151.7% CAGR

Model-based scoring. For information only — not financial advice.

What is Avisa Diagnostics Inc?

operates a clinical-stage medical device company. It is developing the Avisa BreathTest, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its proprietary drug substrates. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 50.00.

Financial Highlights

Investment Breakdown

📈 Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (41)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap50.00
P/E RatioN/A
Dividend YieldN/A
52 Week HighN/A
52 Week LowN/A
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding3M
No. of EmployeesN/A
IndustryMedical Devices
ExchangePINK
Beta0.0266
CurrencyUSD